文献速递炎症性肠病

粪便蛋白组学发现儿童炎症性肠病发作的蛋白质生物标志物

Proteomic Discovery of Stool Protein Biomarkers for Distinguishing Pediatric Inflammatory Bowel Disease Flares.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-09-06

该研究基于质谱的蛋白质组学方法,在10例儿童炎症性肠病患者(活动期或缓解期)的粪便中相对定量了数百种蛋白质,并优先筛选出至少5种在发作期与缓解期丰度范围不同的蛋白质,旨在提高儿童IBD无创监测的特异性。

要点

  • 粪便钙卫蛋白诊断儿童IBD敏感性92%但特异性仅76%。
  • 研究从10例儿童患者粪便中相对定量数百种蛋白质。
  • 优先选出至少5种在发作期与缓解期丰度不同的蛋白质。

核心结论

  • 从儿童IBD患者粪便中鉴定出至少5种在活动期与缓解期丰度范围不同的蛋白质,有潜力辅助提高现有粪便标志物的阴性预测能力。

研究设计与样本

  • 基于质谱的粪便蛋白质组学研究,纳入10例处于活动期或缓解期的儿童IBD患者作为试点队列。

主要发现

  • 在试点队列中相对定量了数百种粪便蛋白质,并优先筛选出至少5种在IBD发作与缓解状态间丰度范围不同的蛋白质。
  • 粪便钙卫蛋白约占中性粒细胞胞质蛋白的60%,诊断IBD平均敏感性93%、特异性96%。
  • 用于诊断儿童IBD时,钙卫蛋白粪便检测敏感性92%、特异性76%。

关键数值与推荐

  • 粪便钙卫蛋白诊断IBD平均敏感性93%、特异性96%。
  • 粪便钙卫蛋白诊断儿童IBD敏感性92%、特异性76%。
  • 研究优先选出至少5种候选粪便蛋白质,需进一步验证。

临床怎么用

  • 儿童IBD无创监测中,钙卫蛋白特异性偏低,可关注多蛋白panel作为补充标志物的潜力。

局限性

  • 研究仅为10例儿童患者的试点队列,候选蛋白需在更大样本中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fecal calprotectin, the heterodimer of S100A8/S100A9, makes up ∼60% of neutrophil cytoplasmic protein content and is a canonical clinical biomarker of gut inflammation.1,2 Fecal calprotectin is commonly used to diagnose inflammatory bowel disease (IBD) and has an average sensitivity of 93% and specificity of 96%.1 For diagnosing pediatric IBD, calprotectin fecal tests have similar sensitivity (92%) but substantially less specificity (76%).1 Low specificity, especially in pediatric patients, means a high likelihood of false negative diagnoses, suggesting that a substantial number of active IBD cases remain undiagnosed and untreated. To improve on calprotectin as an effective IBD monitoring tool in pediatric populations, specificity must be increased. To develop an assay with higher specificity in pediatric patients, we identified a panel of multiple proteins that are present in both IBD flare and remission but have distinct abundance ranges between each condition. From a pilot cohort of 10 pediatric patients in states of either active disease or remission, we discovered and relatively quantified hundreds of stool proteins. Of these, our mass spectrometry-based study prioritized at least 5 that have potential to augment negative predictive power of mucosal-level inflammation alongside fecal biomarkers such as calprotectin.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Casavant E, Park KT, Elias JE, et al. Proteomic Discovery of Stool Protein Biomarkers for Distinguishing Pediatric Inflammatory Bowel Disease Flares. Clin Gastroenterol Hepatol. 2019. PMID: 31499250. doi:10.1016/j.cgh.2019.08.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。